Moses Kitakule, MD
Pulmonary Disease · New Iberia, LANPI 1588602056
Payments from drug & device makers
Across 290 payments — averaging $17.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- Regeneron Healthcare Solutions, Inc.$552
- Sanofi$448
- AstraZeneca$379
- Actelion Pharmaceuticals US, Inc.$343
- Amgen$157
- plus $995 from 17 others
What the payments were for
- Food & beverage$4,99999%
- Education$511%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 142 | $2,176 |
| Regeneron Healthcare Solutions, Inc. | 27 | $552 |
| Sanofi | 20 | $448 |
| AstraZeneca | 22 | $379 |
| Actelion Pharmaceuticals US, Inc. | 16 | $343 |
| Amgen | 8 | $157 |
| Boehringer Ingelheim | 9 | $137 |
| Mylan Specialty L.p. | 7 | $133 |
| Jazz Pharmaceuticals Inc. | 6 | $112 |
| Getinge USA Sales, LLC | 3 | $99 |
| Merck | 4 | $81 |
| Insmed, Inc. | 4 | $73 |
| Sunovion Pharmaceuticals Inc. | 7 | $67 |
| Verona Pharma, Inc. | 3 | $59 |
| Novartis | 3 | $48 |
| Inspire Medical Systems, Inc. | 1 | $45 |
| Harmony Biosciences LLC | 2 | $29 |
| Bayer | 1 | $23 |
| Grifols USA, LLC | 1 | $22 |
| Liquidia Technologies, Inc. | 1 | $19 |
| Gilead | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Mallinckrodt Hospital Products Inc. | 1 | $16 |
How this compares
$5,050 in reported general payments places this provider in the 50th percentile of 189 pulmonary disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 978 | $800,463 |
| Breo ElliptaFluticasone/Vilanterol | 688 | $327,185 |
| Fasenra PenBenralizumab | 34 | $203,492 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 167 | $117,266 |
| SymbicortBudesonide/Formoterol Fumarate | 378 | $112,238 |
| Spiriva HandihalerTiotropium Bromide | 158 | $97,806 |
| XolairOmalizumab | 13 | $72,018 |
| FasenraBenralizumab | 12 | $68,268 |
| Incruse ElliptaUmeclidinium Bromide | 105 | $40,744 |
| Ambrisentan | 12 | $38,823 |
| BreynaBudesonide/Formoterol Fumarate | 168 | $35,216 |
| Spiriva RespimatTiotropium Bromide | 66 | $34,762 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 67 | $32,735 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 55 | $28,685 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 945 | $27,812 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta | $2,176 | $1,205,4401,849 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Fasenra | $379 | $297,772557 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $137 | $86,173163 claims |
| MerckDulera | $81 | $13,68536 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 189 pulmonary disease providers in Louisiana.
Other pulmonary disease in New Iberia
- David GreenShreveport$2M
- Joseph LaskyNew Orleans$1.9M
- Leonardo SeoaneNew Orleans$1.6M
- Ross KlingsbergNew Orleans$1.2M
- Juzar AliNew Orleans$775K
- Hollis O NealBaton Rouge$682K
- Andrea EspinozaHouma$655K
- Ramsy AbdelghaniNew Orleans$474K
- Bennett DeboisblancNew Orleans$457K
- Nereida ParadaNew Orleans$289K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.